Study S001017

A Phase 2, 12-Week, Double-Blind, Randomized, Parallel Group, Multi-Centre Study to Evaluate Efficacy and Safety of GX-G6 on Glycaemic Control Versus Placebo and Open-Label Dulaglutide in Patients With Uncontrolled Type 2 Diabetes Mellitus

ClinicalTrials.gov record

Registration

Registration: NCT03962010
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE2
Masking: DOUBLE
Status: UNKNOWN
Enrollment: 78
Start: 2019-06-01
Primary completion: 2022-06-01
Lead sponsor: Genexine, Inc.
Conditions: Type 2 Diabetes Mellitus
Interventions: DRUG:GX-G6; DRUG:Control
Results posted: FALSE
Individual participant data sharing: UNDECIDED

Registered primary outcomes

Change in HbA1c [Week 12]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.